Tokyo Tape
Sign in
← Cyfuse Biomedical

Annual report

4892.TEDINET S100VGO7
Period2024-01-01 → 2024-12-31
Filed2025-03-26
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 79
MetricValuePeriodScopeSource row
Revenue¥54m2024-01-01 → 2024-12-31StandaloneNet sales
Revenue¥61m2023-01-01 → 2023-12-31StandaloneNet sales
Revenue¥374m2022-01-01 → 2022-12-31dStandaloneNet sales (5-year summary)
Revenue¥708m2021-01-01 → 2021-12-31dStandaloneNet sales (5-year summary)
Revenue¥137m2020-01-01 → 2020-12-31dStandaloneNet sales (5-year summary)
Operating income−¥896m2024-01-01 → 2024-12-31StandaloneOperating income
Operating income−¥697m2023-01-01 → 2023-12-31StandaloneOperating income
Ordinary income−¥870m2024-01-01 → 2024-12-31StandaloneOrdinary income
Ordinary income−¥586m2023-01-01 → 2023-12-31StandaloneOrdinary income
Ordinary income−¥433m2022-01-01 → 2022-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥145m2021-01-01 → 2021-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥327m2020-01-01 → 2020-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥870m2024-01-01 → 2024-12-31StandaloneIncome before income taxes
Profit before tax−¥586m2023-01-01 → 2023-12-31StandaloneIncome before income taxes
Net income−¥872m2024-01-01 → 2024-12-31StandaloneProfit loss
Net income−¥589m2023-01-01 → 2023-12-31StandaloneProfit loss
Net income−¥474m2022-01-01 → 2022-12-31dStandaloneNet income loss (5-year summary)
Net income¥143m2021-01-01 → 2021-12-31dStandaloneNet income loss (5-year summary)
Net income−¥330m2020-01-01 → 2020-12-31dStandaloneNet income loss (5-year summary)
Total assets¥3.5bnat 2024-12-31StandaloneAssets
Total assets¥4.2bnat 2023-12-31StandaloneAssets
Total assets¥4.8bnat 2022-12-31dStandaloneTotal assets (5-year summary)
Total assets¥2.6bnat 2021-12-31dStandaloneTotal assets (5-year summary)
Total assets¥2.2bnat 2020-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥976mat 2024-12-31StandaloneLiabilities
Total liabilities¥1.0bnat 2023-12-31StandaloneLiabilities
Net assets / equity¥2.5bnat 2024-12-31StandaloneNet assets
Net assets / equity¥3.2bnat 2023-12-31StandaloneNet assets
Net assets / equity¥3.8bnat 2022-12-31dStandaloneNet assets
Net assets / equity¥1.9bnat 2021-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥1.5bnat 2020-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥3.1bnat 2024-12-31StandaloneCash and deposits
Cash and deposits¥3.9bnat 2023-12-31StandaloneCash and deposits
Cash & equivalents¥2.1bnat 2024-12-31StandaloneCash and cash equivalents
Cash & equivalents¥2.9bnat 2023-12-31StandaloneCash and cash equivalents
Cash & equivalents¥3.4bnat 2022-12-31dStandaloneCash and cash equivalents
Cash & equivalents¥1.6bnat 2021-12-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥1.3bnat 2020-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥761m2024-01-01 → 2024-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥562m2023-01-01 → 2023-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥404m2022-01-01 → 2022-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow¥162m2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥294m2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥9m2024-01-01 → 2024-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥19m2023-01-01 → 2023-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥431m2022-01-01 → 2022-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥51m2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥264,0002020-01-01 → 2020-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow−¥52m2024-01-01 → 2024-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥18m2023-01-01 → 2023-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥2.7bn2022-01-01 → 2022-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥229m2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥489m2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-108.342024-01-01 → 2024-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-75.422023-01-01 → 2023-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-177.672022-01-01 → 2022-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥285.532021-01-01 → 2021-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-658.342020-01-01 → 2020-12-31dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥304.6at 2024-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥405.71at 2023-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥484.88at 2022-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥-5,183.91at 2021-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥-5,469.44at 2020-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio70.9%at 2024-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio76.0%at 2023-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio78.3%at 2022-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio71.8%at 2021-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio70.5%at 2020-12-31dStandaloneEquity to asset ratio (5-year summary)
ROE8.3%2021-01-01 → 2021-12-31dStandaloneRate of return on equity (5-year summary)
Shares issued8,184,800at 2024-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued7,894,300at 2023-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued7,773,300at 2022-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued1,001at 2021-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued1,001at 2020-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees21at 2024-12-31StandaloneNumber of employees
Employees21at 2023-12-31StandaloneNumber of employees
Employees21at 2022-12-31dStandaloneNumber of employees
Employees22at 2021-12-31dStandaloneNumber of employees
Employees19at 2020-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

All source rows · 789
ItemContextValueUnit
Net cash provided by used in financing activitiesPrior1YearDuration_NonConsolidatedMember18236000JPY
Net cash provided by used in financing activitiesCurrentYearDuration_NonConsolidatedMember-52012000JPY
Net increase decrease in cash and cash equivalentsPrior1YearDuration_NonConsolidatedMember-563534000JPY
Net increase decrease in cash and cash equivalentsCurrentYearDuration_NonConsolidatedMember-821203000JPY
Cash and cash equivalentsPrior2YearInstant_NonConsolidatedMember3437307000JPY
Cash and cash equivalentsPrior1YearInstant_NonConsolidatedMember2873773000JPY
Cash and cash equivalentsPrior1YearInstant_NonConsolidatedMember2873773000JPY
Cash and cash equivalentsCurrentYearInstant_NonConsolidatedMember2052570000JPY
Accumulated impairment loss buildings and accompanying facilitiesPrior1YearInstant_NonConsolidatedMember-16037000JPY
Accumulated impairment loss buildings and accompanying facilitiesCurrentYearInstant_NonConsolidatedMember-26186000JPY
Accumulated depreciation machinery and equipmentPrior1YearInstant_NonConsolidatedMember-103917000JPY
Accumulated depreciation machinery and equipmentCurrentYearInstant_NonConsolidatedMember-104095000JPY
Accumulated depreciation tools furniture and fixturesPrior1YearInstant_NonConsolidatedMember-110205000JPY
Accumulated depreciation tools furniture and fixturesCurrentYearInstant_NonConsolidatedMember-134760000JPY
Directors compensations sgaPrior1YearDuration_NonConsolidatedMember108337000JPY
Directors compensations sgaCurrentYearDuration_NonConsolidatedMember109950000JPY
Salaries allowances and bonuses sgaPrior1YearDuration_NonConsolidatedMember41023000JPY
Salaries allowances and bonuses sgaCurrentYearDuration_NonConsolidatedMember48004000JPY
Research and development expenses sgaPrior1YearDuration_NonConsolidatedMember375584000JPY
Research and development expenses sgaCurrentYearDuration_NonConsolidatedMember469563000JPY
Depreciation sgaPrior1YearDuration_NonConsolidatedMember9891000JPY
Depreciation sgaCurrentYearDuration_NonConsolidatedMember15288000JPY
Research and development expenses sgaPrior1YearDuration_NonConsolidatedMember375584000JPY
Research and development expenses sgaCurrentYearDuration_NonConsolidatedMember469563000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)有価証券報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2025-03-26
Fiscal year cover pageFilingDateInstant
Original text (Japanese)第15期(自　2024年１月１日　至　2024年12月31日)
Company name cover pageFilingDateInstant
Original text (Japanese)株式会社サイフューズ
Company name in english cover pageFilingDateInstantCyfuse Biomedical K.K.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役　　秋　枝　静　香
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都港区三田三丁目５番27号　住友不動産東京三田サウスタワー
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)(03)6435－1885(代表)
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)取締役 ＣＦＯ 経営管理部長　　三　條　真　弘
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都港区三田三丁目５番27号　住友不動産東京三田サウスタワー
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)(03)6435－1885(代表)
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)取締役 ＣＦＯ 経営管理部長　　三　條　真　弘
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE38156
Fund codeFilingDateInstant－
Security codeFilingDateInstant48920
Filer name in japaneseFilingDateInstant
Original text (Japanese)株式会社サイフューズ
Filer name in englishFilingDateInstantCyfuse Biomedical K.K.
Fund name in japaneseFilingDateInstant－
Fund name in englishFilingDateInstant－
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第三号様式
Accounting standardsFilingDateInstantJapan GAAP
Whether consolidated financial statements are preparedFilingDateInstantfalse

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2023-12-31pass rounding
balance sheet identitynon_consolidated 2024-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2022-12-31pass
statement vs summary · net assetsnon_consolidated 2023-12-31pass
statement vs summary · net assetsnon_consolidated 2024-12-31pass
statement vs summary · operating cash flownon_consolidated 2023-01-01/2023-12-31pass
statement vs summary · operating cash flownon_consolidated 2024-01-01/2024-12-31pass
statement vs summary · revenuenon_consolidated 2023-01-01/2023-12-31pass
statement vs summary · revenuenon_consolidated 2024-01-01/2024-12-31pass
statement vs summary · total assetsnon_consolidated 2023-12-31pass
statement vs summary · total assetsnon_consolidated 2024-12-31pass